TET2 and hematologic disorder: Of the TET2 mutations (only accounting for frameshift, nonsense, and missense mutations) reported in COSMIC across all human cancers, 71% (2074/2923) occur in hematological malignancies, with the remaining 29% (849/2923) reported across a plethora of solid tumors.